RTOG 0017: A Phase I Trial of Concurrent Gemcitabine/Carboplatin or Gemcitabine/Paclitaxel and Radiation Therapy (“Ping-Pong Trial”) Followed By Adjuvant Chemotherapy for Patients with Favorable Prognosis Inoperable Stage IIIA/B Non-small Cell Lung Cancer

Jemal, 2007, Cancer statistics, 2007, CA Cancer J Clin, 57, 43, 10.3322/canjclin.57.1.43 Mountain, 1997, Revisions in the international system for staging lung cancer, Chest, 111, 1710, 10.1378/chest.111.6.1710 Perez, 1986, Impact of tumor control on survival in carcinoma of the lung treated with irradiation, Int J Radiat Oncol Biol Phys, 12, 539, 10.1016/0360-3016(86)90061-1 Dillman, 1990, A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer, N Engl J Med, 323, 940, 10.1056/NEJM199010043231403 Sause, 1995, Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer, J Natl Cancer Inst, 87, 198, 10.1093/jnci/87.3.198 Le Chevalier, 1994, Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non small cell lung cancer, Lung Cancer, 10, S239, 10.1016/0169-5002(94)91687-X Curran, 2003, Long-term benefit is observed in a phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410, Proc Am Soc Clin Oncol, 22, 621 Rowell, 2004, Concurrent chemoradiotherapy in non-small cell lung cancer, Cochrane Database Syst Rev, 18, 10.1002/14651858.CD002140.pub2 Furuse, 1999, Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer, J Clin Oncol, 17, 2692, 10.1200/JCO.1999.17.9.2692 Zatloukal, 2004, Concurrent versus sequential chemoradiation for patients with unresected stage III non-small cell lung cancer: Randomized study, Lung Cancer, 46, 87, 10.1016/j.lungcan.2004.03.004 Auperin, 2007, Concomitant radio-chemotherapy (RT-CT) versus sequential RT-CT in locaaly advanced non-small cell lung cancer (NSCLC): a meta-analysis using individual patient data (IPD) from randomised clinical trials (RCTs), J Thorac Oncol, 2, S310, 10.1097/01.JTO.0000283094.86594.8f Scalliet P, Goor C, Galdermans D, et al. Gemcitabine (G) with concurrent chest radiation (XRT) followed by consolidation chemotherapy with gemcitabine plus cisplatin (CDDP): a phase I trial for patients with stage III non-small cell lung cancer (NSCLC) (Abstract). Proc Am Soc Clin Oncol 17:499 11998 (abstract 1923). Athanasiou, 1998, Concurrent chemoradiotherapy with gemcitabine for locally advanced non-small cell lung cancer (NSCLC): preliminary results of a phase II study (Abstract), Ann Oncol, 9, A468 Vokes, 2002, Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small cell lung cancer: cancer and leukemia group B study 9431, J Clin Oncol, 20, 4191, 10.1200/JCO.2002.03.054 Hertel, 1990, Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine), Cancer Res, 50, 4417 Gatzemeier, 2001, Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study, Eur J Cancer, 92, 1213 Negoro, 1994, Results of phase II trials of gemcitabine on non-small cell lung cancer, Proc Amer Soc Clin Oncol, 13, 367 Abratt, 1994, Efficacy and safety profile of gemcitabine in non-small cell lung cancer, J Clin Oncol, 12, 1535, 10.1200/JCO.1994.12.8.1535 Blacklock, 1997, Int J Radiat Oncol Biol Phys, 39, 205, 10.1016/S0360-3016(97)80699-2 Hsu, 1997, Gemcitabine: a cytidine analog active against solid tumors, Am J Health System Pharm, 54, 162, 10.1093/ajhp/54.2.162 Gatzemeier, 1996, Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study, Eur J Cancer, 32, 243, 10.1016/0959-8049(95)00444-0 Abratt, 1994, Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study, J Clin Oncol, 12, 1535, 10.1200/JCO.1994.12.8.1535 Hatcher N, Ranson M, Anderson H, et al. Phase III study of paclitaxel (Taxol) (T) versus best supportive care (BSC) in inoperable non-small cell lung cancer (NSCLC). Presented at the 23rd Congress of the European Society of Medical Oncology, Athens, Greece, November 6–10, 1998. Pritchard, 1996, Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small cell lung cancer: a meta-analysis, Ann Intern Med, 125, 723, 10.7326/0003-4819-125-9-199611010-00003 Gandara, 2000, Gemcitabine/Carboplatin combination regimens: importance of dose schedule, Oncology, 14, 26 Edelman, 1999, Sequential carboplatin/gemcitabine to paclitaxel in advanced non-small cell lung cancer (NSCLC): an effective and well tolerated regimen, Pro Am Soc Clin Oncol, 18, 1936a Aerts, 2006, A phase II study of induction therapy with carboplatin and gemcitabine among patients with locally advanced non-small cell lung cancer, J Thorac Oncol, 1, 532, 10.1016/S1556-0864(15)30355-5 Argiris, 2004, A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer, Lung Cancer, 45, 243, 10.1016/j.lungcan.2004.02.008